The Results of an Open Comparative Study in Parallel Groups of the Efficacy and Safety of the Refnot® (Tumor Necrosis Factor - Thymosin - 1 Alpha Recombinant) Drug in the Treatment of Disseminated Triple Negative Breast Cancer

Medicina
doi 10.29234/2308-9113-2019-7-3-138-149
Full Text
Abstract

Available in full text

Date
Authors
Publisher

INNOPRO

Related search

The POSSIBILITY OF USING TUMOR NECROSIS FACTOR-THYMOSIN-α1 IN NEOADJUVANT CHEMOTHERAPY OF BREAST CANCER

Medical Council
2016English

The Efficacy of Betulinic Acid in Triple-Negative Breast Cancer

SAGE Open Medicine
Medicine
2014English

Treatment With Recombinant Human Tumor Necrosis Factor-Alpha Protects Rats Against the Lethality, Hypotension, and Hypothermia of Gram-Negative Sepsis.

Journal of Clinical Investigation
Medicine
1991English

The Efficacy of Andrographolide and Its Combination With Betulinic Acid in the Treatment of Triple Negative Breast Cancer

Cancer therapy & Oncology International Journal
2017English

The Role of Epidermal Growth Factor Receptor (EGFR) in the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients

Bulletin of Siberian Medicine
Molecular Medicine
2020English

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

The Study of the Efficacy and Safety of Tonsilgon® N in the Treatment of Chronic Pharyngitis

Medical Council
2016English

Long-Term Efficacy and Safety of Exemestane in the Treatment of Breast Cancer

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2013English

Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy